
    
      This will be a Phase 1, open-label, 2-period, fixed-sequence, crossover study to investigate
      the effect of the strong CYP3A inhibitor itraconazole on PF-06463922 PK in approximately 16
      healthy volunteers. The study will consist of potentially up to 6 treatments: single dose of
      PF-06463922 50, 75 or 100 mg and PF-06463922 50, 75 or 100 mg in combination with multiple
      dose itraconazole.
    
  